Skip to main content
SpringerLink
Log in

Effects of Sandostatin on Neuroendocrine Tumours of the Gastrointestinal System

  • Chapter
Peptides in Oncology II

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 129))

Abstract

Before reviewing the effects of Sandostatin on neuroendocrine tumours (NETs) of the gastrointestinal system, it is pertinent to briefly review the clinical features of patients with such tumours.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Anderson J, Bloom SR (1986) Neuroendocrine tumours of the gut: long-term therapy with the somatostatin analogue SMS 201–995.Scand J Gastroenterol 21 [Suppl 119]: 115–128

    Google Scholar 

  • Altimari AF, Bhoopalam N, O’Dorisio T, Lange CL, Sandberg L, Prinzi RA (1986) Use of a somatostatin analog (SMS 201–995) in the glucagonoma syndrome. Surgery 100 (6): 989–996

    PubMed  CAS  Google Scholar 

  • Altman AR, Tschen JA, Rice L (1989) Treatment of malignant carcinoid syndrome with a long-acting somatostatin analogue. Arch Dermatol 125: 394–396

    Article  PubMed  CAS  Google Scholar 

  • Bauer FE, Hummel M, Merki HS, Schulz E, Oeder R, Marbach P (1989) Long-acting somatostatin analog controls acid and gastrin secretion in benign, but in malignant, Zollinger-Ellison syndrome. J Clin Gastroenterol 11 (3): 282–286

    Article  PubMed  CAS  Google Scholar 

  • Boden G, Ryan IG, Eisenschmid BL, Shelmet JJ, Owen OE (1986) Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201–995. N Engl J Med 314 (26): 1686–1689

    Article  PubMed  CAS  Google Scholar 

  • Bonfils S, Ruszniewski P, Laucournet H, Costil V, Rene W, Mignon M (1986) Long-term management of Zollinger-Ellison syndrome with SMS 201–995, a long-lasting somatostatin analog. Program of the 6th International Symposium on Gastrointestinal Hormones, Vancouver, Canada, July 6–10, 1986. Can J Physiol Pharmacol, p 63

    Google Scholar 

  • Brabant G, Muller MJ, Rotsch M et al (1986) Treatment of carcinoid syndrome and VIPoma with a long-acting somatostatin analogue (SMS 201–995). Scan J Gastroenterol 21 [Suppl 1191: 117–180

    Google Scholar 

  • Brown NJ (1990) Octreotide: a long-acting somatostatin analog. Am J Med Sci 300 (4): 267–273

    Article  PubMed  CAS  Google Scholar 

  • Buchanan KD, Shaw C, O’Hare MMT, Dalzell G (1986 a) Evaluation of SMS 201–995 in gastrointestinal APUDomas. Scand J Gastroenterol 21 [Suppl 1191: 199–205

    Google Scholar 

  • Buchanan KD, Johnston CF, O’Hare MMT, Ardill JES, Shaw C, Collins JSA, Watson RGP, Atkinson AB, Hadden DR, Kennedy TL, Sloan JM (1986 b) Neuroendocrine tumours — a european view. Am J Med 81 [Suppl 6B]:14–22

    Google Scholar 

  • Buchanan KD, Collins JSA, Varghese A, Johnston CF, Shaw C (1990a) Sandostatin and the Belfast experience. Digestion 45 [Suppl 11: 11–16

    Article  Google Scholar 

  • Buchanan KD, Shaw C, McGrath SJ, McKillop JM, Harrison E, Johnston CF, McGuigan J, Gibbons JRP (1990 b) Regulatory peptide content of lung and mid-gut carcinoid tumours. Q J Med 77 (282): 1091

    Google Scholar 

  • Cervigon PSG, Navarro JIF, de Diego JS, Asensi AC, Hernandez FC, Jara Albarran A (1987) Tratamiento preoperatorio de la hipoglucemia debida a un insulinoma con el analogo de somatostatina SMS 201–995.Med Clin (Bare) 89 (12): 511–513

    Google Scholar 

  • Ch’ng JLC, Christofides ND, Kraenzlin ME, Keshavarzian A, Burrin JM, Woolf IL, Hodgson HJF, Bloom SR (1985) Growth hormone secretion dynamics in a patient with ectopic growth hormone-releasing factor production. Am J Med 79: 135–138

    Article  PubMed  Google Scholar 

  • Ch’ng JLC, Anderson JV, Williams SJ, Carr DH, Bloom SR (1986) Remission of symptoms during long term treatment of metastatic pancreatic endocrine tumours with long acting somatostatin analogue. Br Med J 292: 981–982

    Article  Google Scholar 

  • Collins JSA, Buchanan KD, Kennedy TL, Johnston CF, Ardill JES, Sloan JM, Mcllrath EM, Russel C (1991) Changing patterns in presentation and management of the Zollinger-Ellison syndrome in Northern Ireland, 1970–1988. Q J Med (New Series) 78 (287): 215–225

    CAS  Google Scholar 

  • Ellison EC, O’Dorisio TM, Sparks J, Mekhjian HS, Fromkes JJ, Woltering EA, Carey LC (1986) Observations on the effect of a somatostatin analog in the Zollinger-Ellison syndrome: implications for the treatment of APUDomas. Surgery 100 (2): 437

    PubMed  CAS  Google Scholar 

  • Geelhoed GW, Bass BL, Mertz SL, Becker KL (1986) Somatostatin analog: effects on hypergastrinemia and hypercalcitoninemia. Surgery 100 (6): 962–970

    PubMed  CAS  Google Scholar 

  • Hearn PR, Ahmed M, Woodhouse NJY (1988) The use of SMS 201–995 (somatostatin analogue) in insulinomas. Hormone Res 29: 211–213

    Article  PubMed  CAS  Google Scholar 

  • Krenning EP, Breeman WAP, Kooij PPM, Lamberts JS, Bakker WH, Koper JW, Ausema L, Reubi JC, Lamberts SWJ (1989) Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1: 242–244

    Article  PubMed  CAS  Google Scholar 

  • Kung AWC, Ma JTC, Wang C, Fu KH, Lam KSL, Yeung RTT, Boey J (1987) Prevention of hypoglycaemia in a patient with pancreatic microadenomatosis by a long-acting somatostatin analogue SMS 201–995. Clin Endocrinol 27: 469–473

    Article  CAS  Google Scholar 

  • Kvols LK, Buck M, Moertel CG, Schutt AJ, Rubin J, O’Connell MJ, Hahn RG (1987) Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201995). Ann Intern Med 107: 162–168

    PubMed  CAS  Google Scholar 

  • Lamberts SWJ, Bakker WH, Reubi J-C, Krenning EP (1990) Clinical application of somatostatin analogs. Part I. Metabolism 39 (9) [Suppl 2]: 152–155

    Google Scholar 

  • Marsh HM, Martin JK, Kvols LK et al (1987) Carcinoid crisis during anesthesia: successful treatment with a somatostatin analogue. Anesthesiology 66: 89–91

    Article  PubMed  CAS  Google Scholar 

  • Maton PN, O’Dorisio TM, O’Dorisio MS, Malarkey WB, Gower WJ Jr, Gardner JD, Jensen RT (1986) Successful therapy of pancreatic cholera with the long-acting somatostatin analogue SMS 201–995. Relation between plasma concentrations of drug and clinical and biochemical responses. Scand J Gastroenterol 21 [Suppl 119]: 181–186

    Article  Google Scholar 

  • Maton PN, Gardner JD, Jensen RT (1989) Use of long-acting somatostatin analog SMS 201–995 in patients with pancreatic islet cell tumors. Dig Dis Sci 34 (3): 28S - 39S

    Article  PubMed  CAS  Google Scholar 

  • Mozell E, Woltering EA, O’Dorisio TM, Fletcher WS, Sinclair AJ, Hill D (1990) Effect of somatostatin analog on peptide release and tumor growth in the Zollinger-Ellison syndrome. Surg Gynecol Obstet 170: 476–484

    PubMed  CAS  Google Scholar 

  • Norheim I, Theodorsson-Norheim E, Brodin E, Oberg K (1986) Tachykinins in carcinoid tumors; their use as a tumor marker and possible role in the carcinoid flush. J Clin Endocrinol Metab 63: 605

    Article  PubMed  CAS  Google Scholar 

  • Reubi JC, Laissue J, Krenning E, Lamberts SWJ (1992) Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol 43 (1–3): 27–35

    Article  PubMed  CAS  Google Scholar 

  • Ruskone A, Rene E, Chayvialle JA, Bonin N, Pignal F, Kremer M, Bonfils S, Rambaud JC (1982) Effect of somatostatin on diarrhea and on small intestinal water and electrolyte transport in a patient with pancreatic cholera. Dig Dis Sci 27: 459–466

    Article  PubMed  CAS  Google Scholar 

  • Stehouwer CDA, Lems WF, Fischer HRA, Hackeng WHL (1989) Malignant insulinoma: is combined treatment with verapamil and the long-acting somatostatin analogue octreotide (SMS 201–995) more effective than single therapy with either drug? Neth J Med 35: 86–94

    PubMed  CAS  Google Scholar 

  • Timmer R, Koningsberger JC, Erkelens DW, Thijssen JHH, Lips CJM, Koppeschaar HPF (1991) No effect of the long-acting somatostatin analogue octreotide in patients with insulinoma. Neth J Med 38: 199–203

    PubMed  CAS  Google Scholar 

  • Verner JV, Morrison AB (1958) Islet cell tumour and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med 25: 374–380

    Article  PubMed  CAS  Google Scholar 

  • Verschoor L, Uitterlinden P, Lamberts SWJ, del Pozo E (1986) On the use of a new somatostatin analogue in the treatment of hypoglycaemia in patients with insulinoma. Clin Endocrinol 25: 555 — 560

    Google Scholar 

  • Vinik A, Moattari AR (1989) Use of somatostatin analog in management of carcinoid syndrome. Dig Dis Sci 34 (3): 14S - 27S

    Article  PubMed  CAS  Google Scholar 

  • Von Werder K, Losa M, Muller OA, Schweiberer L, Fahlbusch R, del Pozo E (1984) Treatment of metastasizing GRF-producing tumor with a long-acting somatostatin analogue. Lancet ii: 282 — 283

    Google Scholar 

  • Von Werder K, Losa M, Stalla GK, Muller OA, Mayr B, Schweiberer L, Fahlbusch LR (1986) Long-term treatment of a metastasizing GRFoma with a somatostatin analogue (SMS 201–995) in a girl with gigantism. Scand J Gastroenterol 21 [Suppl 1191: 238–242

    Article  Google Scholar 

  • Watson RGP, Johnston CF, O’Hare MMT, Anderson JR, Wilson BG, Coillins JSA, Sloan JM, Buchanan KD (1989) The frequency of gastrointestinal endocrine tumours in a well-defined population — Northern Ireland 1970–1985. Quart J Med (New Series) 72 (267): 647–657

    CAS  Google Scholar 

  • Williams G, Bloom SR (1987) Long-term treatment of VIPoma and glucagonoma with Sandostatin. In: O’Dorisio TM (ed) Sandostatin in the treatment of gastroenteropancreatic endocrine tumors. Springer, Berlin Heidelberg New York

    Google Scholar 

  • Wilson DM, Hoffman AR (1985) Reduction of pituitary size in a patient with a GRF secreting islet cell tumor by continuous infusion of a somatostatin analogue. Program of the Endocrine Society 6th Annual Meeting, Baltimore, Maryland, June 19–21, 1985, p 39

    Google Scholar 

  • Wilson DM, Hoffman AR (1986) Reduction of pituitary size by the somatostatin analogue SMS 201–995 in a patient with an islet cell tumour secreting growth hormone releasing factor. Acta Endocrinol 113: 23–28

    PubMed  CAS  Google Scholar 

  • Woods HF, Bax NDS, Ainsworth I (1990) Abdominal carcinoid tumours in Sheffield. Dig 45 [Suppl 11: 17–22

    Google Scholar 

  • Wynick D, Bloom SR (1991) The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumours. J Clin Endocrinol Metab 73 (1): 1–3

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Institute of Clinical Science, The Queen’s University of Belfast, Grosvenor Road, Belfast, BT12 68J, Northern Ireland

    K. D. Buchanan

Authors
  1. K. D. Buchanan
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Innere Medizin II: Onkologie — Hämatologie — Endokrinologie — Stoffwechselerkrankungen, Klinikum der Friedrich-Schiller-Universität Jena, Erlanger Allee 101, O-6902, Jena-Lobeda, Germany

    K. Höffken

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Buchanan, K.D. (1993). Effects of Sandostatin on Neuroendocrine Tumours of the Gastrointestinal System. In: Höffken, K. (eds) Peptides in Oncology II. Recent Results in Cancer Research, vol 129. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84956-5_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-84956-5_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-84958-9

  • Online ISBN: 978-3-642-84956-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation